We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Currently, the therapy is approved to treat those with the condition who have factor VIII inhibitors, that is antibodies causing resistance to replacement clotting factors.